Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois(Kliniken Essen-Mitte), Gunnar B. Kristensen(Oslo University Hospital), Isabelle Ray‐Coquard(Université Claude Bernard Lyon 1), Alexander Reuß, Sandro Pignata, Nicoletta Colombo(European Institute of Oncology), Ursula Denison(Gesundheit Österreich), Ignace Vergote, José María Del Campo(Vall d'Hebron Hospital Universitari), Petronella B. Ottevanger(Radboud University Nijmegen), Martin Heubner(University of Duisburg-Essen), Thomas Minarik, Emmanuel Sevin(Centre François Baclesse), Nikolaus de Gregorio(University Hospital Ulm), Mariusz Bidziński(Jan Kochanowski University), Jacobus Pfisterer(Clinical Research Center Kiel), Susanne Malander(Lund University), Felix Hilpert, Mansoor Raza Mirza(Copenhagen University Hospital), Giovanni Scambia(Università Cattolica del Sacro Cuore), Werner Meier(Evangelisches Krankenhaus Düsseldorf), Maria Ornella Nicoletto(Istituto Oncologico Veneto), Line Bjørge(Haukeland University Hospital), Alain Lortholary, Martin Oliver Sailer(Boehringer Ingelheim (Germany)), Michael Merger(Boehringer Ingelheim (Germany)), Philipp Harter(Kliniken Essen-Mitte)
Cited by 209Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis